Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dark Adaptation Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

NCT07803588
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
AdaptDx Tabletop vs AdaptDx Pro
Diagnostic Test
Lead sponsor
AdaptDx, Inc.
Industry
Eligibility
22 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Visual Mode Switching in Color Perception

NCT05779228
View directory record Official record
Conditions
Perception of Things Changing Color, Adaptive Behavior
Interventions
Mode Switching Training
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting Phase 2 Interventional

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

NCT04735263
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Atorvastatin 80mg
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Not applicable Interventional

"Night Vision and Carotenoids"

NCT04741763
View directory record Official record
Conditions
Macular Degeneration
Interventions
EyePromise Visual Edge
Dietary Supplement
Lead sponsor
Robert Davis
Other
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
North Chicago, Illinois • Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Early Phase 1 Interventional Results available

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

NCT03478865
View directory record Official record
Conditions
AMD
Interventions
Vitamin A palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli

NCT06961864
View directory record Official record
Conditions
Visual Snow Syndrome, Migraine, Healthy
Interventions
Visual Adaptation, Assessments and Questionnaires, Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Imaging (MRS)
Behavioral · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Active, not recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783
View directory record Official record
Conditions
Vision Loss Night, Vision Disorders
Interventions
0.75% Phentolamine Ophthalmic Solution, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Investigation of Macular Pigment Augmentation on Dark Adaptation

NCT00478439
View directory record Official record
Conditions
Aging, Age-Related Macular Degeneration
Interventions
ZeaVision EyePromise Restore, Multivitamin
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 26, 2010 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

NCT06619405
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Streetlab VR
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
50 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
View directory record Official record
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 7, 2026, 3:58 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NCT05045703
View directory record Official record
Conditions
Choroideremia
Interventions
Vitamin A palmitate
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
15 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

NCT01999764
View directory record Official record
Conditions
Impaired Dark Adaptation
Interventions
QLT091001, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Artesia, California • Santa Barbara, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting No phase listed Observational

Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes

NCT07270133
View directory record Official record
Conditions
Diabetic Retinal Disease
Interventions
Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography
Diagnostic Test · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visual Activity Evoked by Infrared in Humans After Dark Adaptation

NCT02909985
View directory record Official record
Conditions
Age Related Macular Degeneration, Retinitis Pigmentosa, Congenital Stationary Night Blindness, Colorblindness
Interventions
Tungsten halogen light with narrow bandpass filters
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rod and Cone Mediated Function in Retinal Disease

NCT02617966
View directory record Official record
Conditions
Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 3:58 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Facilitating Adjustment to Simulated Jet Lag

NCT05382923
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorder, Jet Lag Type
Interventions
Bright Light, Bright Light + Exercise + Melatonin, Control
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Targeting Insomnia in School Aged Children With Autism Spectrum Disorder

NCT04545606
View directory record Official record
Conditions
Insomnia Chronic, Autism Spectrum Disorder
Interventions
In-Person CBT for insomnia in children with autism, Remote CBT for insomnia in children with autism, Remote sleep hygiene and related education (SHARE) for insomnia in children with autism
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
6 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 7, 2026, 3:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 7, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Color Perception Under LED Red/Green and Green Dominant Light

NCT01927536
View directory record Official record
Conditions
Color Blindness, Acquired
Interventions
White LED Flashlight, Red/Green Green Dominant LED Flashlight
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 66 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 7, 2026, 3:58 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Visual Function Tests in Age-related Macular Degeneration

NCT03275753
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Visual Function Tests
Other
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 7, 2026, 3:58 PM EDT
Completed Early Phase 1 Interventional Results available

Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

NCT03478878
View directory record Official record
Conditions
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions
Vitamin A Palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 7, 2026, 3:58 PM EDT